Articoli di riviste sul tema "He53"
Cita una fonte nei formati APA, MLA, Chicago, Harvard e in molti altri stili
Vedi i top-50 articoli di riviste per l'attività di ricerca sul tema "He53".
Accanto a ogni fonte nell'elenco di riferimenti c'è un pulsante "Aggiungi alla bibliografia". Premilo e genereremo automaticamente la citazione bibliografica dell'opera scelta nello stile citazionale di cui hai bisogno: APA, MLA, Harvard, Chicago, Vancouver ecc.
Puoi anche scaricare il testo completo della pubblicazione scientifica nel formato .pdf e leggere online l'abstract (il sommario) dell'opera se è presente nei metadati.
Vedi gli articoli di riviste di molte aree scientifiche e compila una bibliografia corretta.
Kent, Matthew R., Delia Calderon, Katherine M. Silvius, Jack P. Kucinski, Collette A. LaVigne, Matthew V. Cannon e Genevieve C. Kendall. "Abstract 3533: Zebrafish her3 knockout impacts developmental and rhabdomyosarcoma-related gene signatures". Cancer Research 83, n. 7_Supplement (4 aprile 2023): 3533. http://dx.doi.org/10.1158/1538-7445.am2023-3533.
Testo completoBeckford Vera, Denis, Jason Li, Le-Cun Xu, Debbie Lewis, Amanda Chin, Patrik Brodin, Mary Chen, Monideepa Roy e Helen Kotanides. "Preclinical evaluation of novel HER3-targeting radioconjugates for the imaging and treatment of HER3-expressing cancers." Journal of Clinical Oncology 41, n. 16_suppl (1 giugno 2023): e15114-e15114. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e15114.
Testo completoKoyama, Kumiko, Hirokazu Ishikawa, Manabu Abe, Yoshinobu Shiose, Suguru Ueno, Yang Qiu, Kenji Nakamaru e Masato Murakami. "Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression". PLOS ONE 17, n. 5 (3 maggio 2022): e0267027. http://dx.doi.org/10.1371/journal.pone.0267027.
Testo completoKomatsu, Nagiho, Saori Sato, Sumie Muramatsu, Ryuichi Nakamura e Kumiko Koyama. "Abstract 3996: The impact of HER3 dynamics on the efficacy of HER3-DXd, a novel HER3 directed antibody-drug conjugate". Cancer Research 83, n. 7_Supplement (4 aprile 2023): 3996. http://dx.doi.org/10.1158/1538-7445.am2023-3996.
Testo completoO'Hare, Thomas, Jaclyn Cleveland, Valerie M. Jansen e David Dornan. "Abstract 3121: Therapeutic potential of a HER3 antibody-drug conjugate for the treatment of HER3-expressing cancers". Cancer Research 84, n. 6_Supplement (22 marzo 2024): 3121. http://dx.doi.org/10.1158/1538-7445.am2024-3121.
Testo completoBeckford-Vera, Denis, Megan McCloskey, Jason Li, Caroline Jennings, Le-Cun Xu, Debbie Lewis, Patrik Brodin et al. "Abstract 5040: Novel HER3 targeting antibody radioconjugates, 225Ac-HER3 ARC and 177Lu-HER3 ARC, exhibit potent antitumor efficacy in HER3-positive solid tumors". Cancer Research 83, n. 7_Supplement (4 aprile 2023): 5040. http://dx.doi.org/10.1158/1538-7445.am2023-5040.
Testo completoToy, Weiyi, Dipti Thakkar, Roberto Magallanes, Sharon Wu, Ming Poi, Alejandro Mas, Konrad Paszkiewicz, Piers Ingram e Jerome Boyd-Kirkup. "Abstract 5796: A HER3 antibody that uniquely blocks the HER3 heterodimerization interface effectively inhibits tumor growth in pre-clinical models with potentially oncogenic HER3 mutations". Cancer Research 84, n. 6_Supplement (22 marzo 2024): 5796. http://dx.doi.org/10.1158/1538-7445.am2024-5796.
Testo completoBeckford-Vera, Denis, Jason Li, Megan McCloskey, Caroline Jennings, Amanda Chin, Qing Liang, Jesse Hwang, Monideepa Roy, Mary Chen e Helen Kotanides. "Abstract 3306: Targeting HER3 receptor positive cancers with a novel anti-HER3 antibody radioconjugate (ARC)". Cancer Research 82, n. 12_Supplement (15 giugno 2022): 3306. http://dx.doi.org/10.1158/1538-7445.am2022-3306.
Testo completoScartozzi, M., A. Mandolesi, R. Giampieri, A. Zaniboni, E. Galizia, L. Giustini, R. R. Silva, R. Berardi, I. Bearzi e S. Cascinu. "The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan/cetuximab." Journal of Clinical Oncology 29, n. 4_suppl (1 febbraio 2011): 404. http://dx.doi.org/10.1200/jco.2011.29.4_suppl.404.
Testo completoMartinez Lago, Nieves, Ihab Abdulkader, Dora Insua Santamaria, Patricia Viaño Nuñez, Juan Jose Carrera, Jose Ramón Antunez Lopez, Maria Elena Padin Iruegas e Rafael López López. "Assessment and prognostic impact of a new classification using HER2 and HER3 status in resected gastric cancer in a european cohort." Journal of Clinical Oncology 36, n. 4_suppl (1 febbraio 2018): 65. http://dx.doi.org/10.1200/jco.2018.36.4_suppl.65.
Testo completoMukherjee, Sumit, Debbie Lewis, Jason Li, Le-Cun Xu, Amanda Chin, Mary Chen, Monideepa Roy et al. "Abstract A149: Characterization of HER3 targeted radioligand therapy using molecular imaging". Molecular Cancer Therapeutics 22, n. 12_Supplement (1 dicembre 2023): A149. http://dx.doi.org/10.1158/1535-7163.targ-23-a149.
Testo completoXie, Xuemei, Jangsoon Lee, Jon A. Fuson, Huey Liu, Young Jin Gi, Pang-Dian Fan, Kumiko Koyama, Debu Tripathy e Naoto T. Ueno. "Abstract LB088: Targeting ATR enhances the antitumor efficacy of patritumab deruxtecan (HER3-DXd) in tamoxifen-resistant ER+ breast cancer cells by reprogramming cell cycle progression". Cancer Research 82, n. 12_Supplement (15 giugno 2022): LB088. http://dx.doi.org/10.1158/1538-7445.am2022-lb088.
Testo completoBeckford-Vera, Denis, Jason Li, Caroline Jennings, Megan McCloskey, Amanda Chin, Qing Liang, Jesse Hwang, Monideepa Roy, Mary Chen e Helen Kotanides. "Abstract 609: Anti-HER3 radioimmunotherapy enhances the anti-tumor effects of CD47 blockade in solid tumors". Cancer Research 82, n. 12_Supplement (15 giugno 2022): 609. http://dx.doi.org/10.1158/1538-7445.am2022-609.
Testo completoChang, Chi-Son, Jung In Shim, Sun-Ju Byeon, Eun Jin Lee, Yoo-Young Lee, Tae-Joong Kim, Jeong-Won Lee, Byoung-Gie Kim e Chel Hun Choi. "Prognostic Significance of HER3 Expression in Patients with Cervical Cancer". Cancers 14, n. 9 (25 aprile 2022): 2139. http://dx.doi.org/10.3390/cancers14092139.
Testo completoChang, Chi-Son, Jung In Shim, Sun-Ju Byeon, Eun Jin Lee, Yoo-Young Lee, Tae-Joong Kim, Jeong-Won Lee, Byoung-Gie Kim e Chel Hun Choi. "Prognostic Significance of HER3 Expression in Patients with Cervical Cancer". Cancers 14, n. 9 (25 aprile 2022): 2139. http://dx.doi.org/10.3390/cancers14092139.
Testo completoAmin, Dhara N., Natalia Sergina, Lionel Lim, Andrei Goga e Mark M. Moasser. "HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells". Biochemical Journal 447, n. 3 (5 ottobre 2012): 417–25. http://dx.doi.org/10.1042/bj20120724.
Testo completoRajendran, Rithika, Coen Johannes Gerardus Lap, Fayez Estephan, Shanshan Liu, Ramesh Subrahmanyam, Guoqing Diao, Victor Nava e Maneesh Rajiv Jain. "Prevalence of HER3 expression in prostate adenocarcinoma and its clinicopathological characteristics." Journal of Clinical Oncology 42, n. 16_suppl (1 giugno 2024): 5019. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.5019.
Testo completoYonesaka, Kimio, Junko Tanizaki, Osamu Maenishi, Koji Haratani, Hisato Kawakami, Kaoru Tanaka, Hidetoshi Hayashi et al. "Dynamics of HER3 and its correlated gene expression profile in EGFR-mutated NSCLC tumor treated with EGFR-TKI toward enhancing effectiveness of patritumab deruxtecan (HER3-DXd; U3-1402)." Journal of Clinical Oncology 40, n. 16_suppl (1 giugno 2022): e21175-e21175. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e21175.
Testo completoYonesaka, Kimio, Junko Tanizaki, Osamu Maenishi, Koji Haratani, Hisato Kawakami, Kaoru Tanaka, Hidetoshi Hayashi et al. "Dynamics of HER3 and its correlated gene expression profile in EGFR-mutated NSCLC tumor treated with EGFR-TKI toward enhancing effectiveness of patritumab deruxtecan (HER3-DXd; U3-1402)." Journal of Clinical Oncology 40, n. 16_suppl (1 giugno 2022): e21175-e21175. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e21175.
Testo completoKim, Joori, Jeong-Oh Kim, Youn Soo Lee, Jung-Young Shin, Min Young Kim, Mi-Ran Lee, Seoree Kim et al. "The changes of HER3 expression in head and neck cancer patients treated with induction chemotherapy." Journal of Clinical Oncology 41, n. 16_suppl (1 giugno 2023): e18004-e18004. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e18004.
Testo completoMishra, Rosalin, Mary Kate Kilroy, Wasim Feroz, Hima Patel, Samar Alanazi e Joan T. Garrett. "Abstract 3916: role of her3 v104l mutation on tumor growth and her3 stabilization". Cancer Research 83, n. 7_Supplement (4 aprile 2023): 3916. http://dx.doi.org/10.1158/1538-7445.am2023-3916.
Testo completoÒdena, Andreu, Laia Monserrat, Fara Brasó-Maristany, Marta Guzmán, Judit Grueso, Olga Rodríguez, Maurizio Scaltriti et al. "Abstract P5-13-14: Antitumor activity of patritumab deruxtecan (HER3-DXd), a HER3-directed antibody drug conjugate (ADC) across a diverse panel of breast cancer (BC) patient-derived xenografts (PDXs)". Cancer Research 82, n. 4_Supplement (15 febbraio 2022): P5–13–14—P5–13–14. http://dx.doi.org/10.1158/1538-7445.sabcs21-p5-13-14.
Testo completoManickavasagar, Thubeena, Wei Yuan, Suzanne Carreira, Bora Gurel, Susana Miranda, Ana Ferreira, Mateus Crespo et al. "HER3 expression and MEK activation in non-small-cell lung carcinoma". Lung Cancer Management 10, n. 2 (giugno 2021): LMT48. http://dx.doi.org/10.2217/lmt-2020-0031.
Testo completoRathore, Moeez Ghani, Wei Zhang, Michel'le Wright, Jordan Winter, Yamu Li, Zhenghe Wang e Rui Wang. "Abstract 3177: Liver endothelium secreted LRG1 is a novel ligand of HER3 to promote metastatic colorectal cancer growth". Cancer Research 82, n. 12_Supplement (15 giugno 2022): 3177. http://dx.doi.org/10.1158/1538-7445.am2022-3177.
Testo completoNishioka, Mariko, Chigusa Morizane, Mao Okada, Tomoyuki Satake, Nobuyoshi Hiraoka, Satoshi Nara, Tomoya Kakegawa et al. "HER3 expression status following systemic chemotherapy treatment in biliary tract cancers." Journal of Clinical Oncology 41, n. 16_suppl (1 giugno 2023): e16153-e16153. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e16153.
Testo completoXie, Xuemei, Jangsoon Lee, Jon A. Fuson, Huey Liu, Young J. Gi, Thanasis Poullikkas, Pang-Dian Fan, Kumiko Koyama, Debu Tripathy e Naoto T. Ueno. "Abstract LB042: Targeting ATR enhances the antitumor efficacy of patritumab deruxtecan (HER3-DXd)in tamoxifen-resistant ER+ breast cancer cells by inducing DNA damage and apoptosis". Cancer Research 83, n. 8_Supplement (14 aprile 2023): LB042. http://dx.doi.org/10.1158/1538-7445.am2023-lb042.
Testo completoKilroy, Mary Kate, SoYoung Park, Wasim Feroz, Hima Patel, Rosalin Mishra, Samar Alanazi e Joan T. Garrett. "HER3 Alterations in Cancer and Potential Clinical Implications". Cancers 14, n. 24 (14 dicembre 2022): 6174. http://dx.doi.org/10.3390/cancers14246174.
Testo completoMishra, Rosalin, Mary Kate Kilroy, Hima Patel, Samar Alanazi e Joan T. Garrett. "Abstract 5412: Role of her3 mutations on breast cancer oncogenesis". Cancer Research 82, n. 12_Supplement (15 giugno 2022): 5412. http://dx.doi.org/10.1158/1538-7445.am2022-5412.
Testo completoHwang, Hae Min, So Hyeon Kim, Sujin Ham, Minyoung Lee, Youlim Noh, Yu-Jin Kim, Changyun Lee et al. "Abstract C120: Antitumor effect of HER3-DXd, an antibody-drug conjugate targeting HER3, in gastric cancer cell lines". Molecular Cancer Therapeutics 22, n. 12_Supplement (1 dicembre 2023): C120. http://dx.doi.org/10.1158/1535-7163.targ-23-c120.
Testo completoHong, Woojae, Jeon Hwang-Bo, Hyelin Jeon, Minsung Ko, Joongyeon Choi, Yong-Joon Jeong, Jae-Hyun Park et al. "A Comparative Study of the Hepatoprotective Effect of Centella asiatica Extract (CA-HE50) on Lipopolysaccharide/d-galactosamine-Induced Acute Liver Injury in C57BL/6 Mice". Nutrients 13, n. 11 (15 novembre 2021): 4090. http://dx.doi.org/10.3390/nu13114090.
Testo completoTanner, Berno, Dirk Hasenclever, Katja Stern, Wiebke Schormann, Martin Bezler, Matthias Hermes, Marc Brulport et al. "ErbB-3 Predicts Survival in Ovarian Cancer". Journal of Clinical Oncology 24, n. 26 (10 settembre 2006): 4317–23. http://dx.doi.org/10.1200/jco.2005.04.8397.
Testo completoLi, Zhuolin, Chengzhang Shang, Gao An, Chaoshe Guo, W. Frank An e Yi Yang. "Abstract 2619: A novel EGFR × HER3-targeting bispecific antibody drug-conjugate, BCG019, demonstrates robust anti-tumor efficacy in preclinical evaluation". Cancer Research 84, n. 6_Supplement (22 marzo 2024): 2619. http://dx.doi.org/10.1158/1538-7445.am2024-2619.
Testo completoCruz, Rodrigo G. B., Stephen F. Madden, Cathy E. Richards, Sri HariKrishna Vellanki, Hanne Jahns, Lance Hudson, Joanna Fay et al. "Human Epidermal Growth Factor Receptor-3 Expression Is Regulated at Transcriptional Level in Breast Cancer Settings by Junctional Adhesion Molecule-A via a Pathway Involving Beta-Catenin and FOXA1". Cancers 13, n. 4 (19 febbraio 2021): 871. http://dx.doi.org/10.3390/cancers13040871.
Testo completoSatake, Tomoyuki, Chigusa Morizane, Mao Okada, Mariko Nishioka, Nobuyoshi Hiraoka, Satoshi Nara, Tomoya Kakegawa et al. "Abstract 3405: Changes in HER3 expression associated with chemotherapy for pancreatic cancer". Cancer Research 83, n. 7_Supplement (4 aprile 2023): 3405. http://dx.doi.org/10.1158/1538-7445.am2023-3405.
Testo completoLim, Malcolm, Tam H. Nguyen, Colleen Niland, Lynne E. Reid, Parmjit S. Jat, Jodi M. Saunus e Sunil R. Lakhani. "Landscape of Epidermal Growth Factor Receptor Heterodimers in Brain Metastases". Cancers 14, n. 3 (21 gennaio 2022): 533. http://dx.doi.org/10.3390/cancers14030533.
Testo completoKurmasheva, Raushan, Peter Houghton, Vanessa Del Pozo, Samson Ghilu, Ryuichi Nakamura, Pang-Dian Fan, Emily Jocoy et al. "Abstract 1088: An evaluation of patritumab deruxtecan (HER3-DXd, U3-1402) against pediatric PDX models for hepatoblastoma and rhabdomyosarcoma - A report from the NCI PIVOT Program". Cancer Research 84, n. 6_Supplement (22 marzo 2024): 1088. http://dx.doi.org/10.1158/1538-7445.am2024-1088.
Testo completoBawa, I. Gusti Agung Gede, Sri Rahayu Santi, Wiwik Susanah Rita, Olan Suryanadi e Gek Indyan. "Active compounds of Michelia champaca bark extract against Curvularia verruculosa fungi causing leaf spot disease in rice (Oryza sativa L.)". Journal of Applied and Natural Science 16, n. 1 (20 marzo 2024): 420–26. http://dx.doi.org/10.31018/jans.v16i1.5406.
Testo completoRomaniello, Donatella, Ilaria Marrocco, Nishanth Belugali Nataraj, Irene Ferrer, Diana Drago-Garcia, Itay Vaknin, Roni Oren et al. "Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor". Cancers 12, n. 9 (24 agosto 2020): 2394. http://dx.doi.org/10.3390/cancers12092394.
Testo completoJacobs, Bart, Loredana Vecchione, Nicholas Hoe, Jef De Schutter, Bart Biesmans, Sharat Singh e Sabine Tejpar. "Effect of EGFR inhibition on HER3/PI3K activation by feedback induction of ErbB heterodimers in cetuximab-sensitive colon cancer cells." Journal of Clinical Oncology 31, n. 15_suppl (20 maggio 2013): 3626. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.3626.
Testo completoPark, Yeon Hee, Hyun Ae Jung, Won Jin Chang, Moon Ki Choi, Jung Yong Hong, Oh-Nam Ok, Jeong Ju Seo et al. "Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) patients who received taxane plus trastuzumab treatment." Journal of Clinical Oncology 31, n. 15_suppl (20 maggio 2013): 637. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.637.
Testo completoKilroy, Mary K., Rosalin Mishra, Anastasia Stupecki, Wasim Feroz, Samar Alanazi e Joan T. Garrett. "Abstract 3988: The role of HER3 mutations in the progression of colon cancer and modulation of drug sensitivity and resistance". Cancer Research 83, n. 7_Supplement (4 aprile 2023): 3988. http://dx.doi.org/10.1158/1538-7445.am2023-3988.
Testo completoRathore, Moeez Ghani, Kimberly Curry, Christina Boutros, Zhenghe Wang, Jordan Winter e Rui Wang. "Abstract 3082: The liver microenvironment promotes glycolysis in metastatic colorectal cancer by activating her3". Cancer Research 84, n. 6_Supplement (22 marzo 2024): 3082. http://dx.doi.org/10.1158/1538-7445.am2024-3082.
Testo completoRaghav, Kanwal Pratap Singh, Takayuki Yoshino, Hiroya Taniguchi, Sabine Tejpar, Arndt Vogel, Zev A. Wainberg, Kensei Yamaguchi et al. "An open-label, phase II study of patritumab deruxtecan (HER3-DXd, U3-1402) in patients (pts) with previously treated advanced/metastatic colorectal cancer (CRC)." Journal of Clinical Oncology 39, n. 3_suppl (20 gennaio 2021): TPS157. http://dx.doi.org/10.1200/jco.2021.39.3_suppl.tps157.
Testo completoKilroy, Mary K., Briley Park, Rosalin Mishra, Wasim Feroz, Cecilia Wischmeier e Joan T. Garrett. "Abstract 7150: Molecular insights into the oncogenic influence between mutant HER3, mutant KRAS, and their synergistic interplay in colorectal cancer pathogenesis". Cancer Research 84, n. 6_Supplement (22 marzo 2024): 7150. http://dx.doi.org/10.1158/1538-7445.am2024-7150.
Testo completoWang, Lina, Meijun Xiong, Xinju Gao, Chengang Zhou, Yu Han, Yanchun Li, Junhao Wang, Lili Shi, Gang Qin e Paul H. Song. "Abstract 2114: Enhancing therapeutic strategies for osimertinib-resistant EGFR-mutant NSCLC: A HER3 dual-payload ADC (dpADC) with topoisomerase I and EGFR tyrosine kinase inhibitor". Cancer Research 84, n. 6_Supplement (22 marzo 2024): 2114. http://dx.doi.org/10.1158/1538-7445.am2024-2114.
Testo completoBartsch, Rupert, Anna Sophie Berghoff, Zsuzsanna Bago-Horvath, Matthias Preusser, Guenther G. Steger, Margareta Rudas, Peter Birner e Christoph Zielinski. "Coexpression of HER3 as a predictor of survival in HER2-positve breast cancer patients." Journal of Clinical Oncology 31, n. 15_suppl (20 maggio 2013): 611. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.611.
Testo completoAl-Akhrass, Hussein, James R. W. Conway, Annemarie Svane Aavild Poulsen, Ilkka Paatero, Jasmin Kaivola, Artur Padzik, Olav M. Andersen e Johanna Ivaska. "A feed-forward loop between SorLA and HER3 determines heregulin response and neratinib resistance". Oncogene 40, n. 7 (8 gennaio 2021): 1300–1317. http://dx.doi.org/10.1038/s41388-020-01604-5.
Testo completoAlanazi, Samar M., Rosalin Mishra, Hima Patel, Mary K. Kilroy e Joan T. Garrett. "Abstract 5661: HER2 inhibition increases non-muscle myosin IIa to promote tumorigenesis in HER2+ breast cancers". Cancer Research 82, n. 12_Supplement (15 giugno 2022): 5661. http://dx.doi.org/10.1158/1538-7445.am2022-5661.
Testo completoBoutros, Christina S., Alexander W. Loftus, Moeez Rathore, Mehrdad Zarei, Kimberly Curry, Jordan M. Winter e Rui Wang. "Abstract 445: Determining the molecular and biologic effects of HER3 and IDH1 antagonism on liver endothelium-PDAC crosstalk". Cancer Research 84, n. 6_Supplement (22 marzo 2024): 445. http://dx.doi.org/10.1158/1538-7445.am2024-445.
Testo completoKojima, Yuki, Kazuki Sudo, Hiroshi Yoshida, Shu Yazaki, Momoko Tokura, Shosuke Kita, Kasumi Yamamoto et al. "Abstract 5083: Changes in HER3 expression profiles between initial diagnosis and recurrence in gynecologic cancers". Cancer Research 82, n. 12_Supplement (15 giugno 2022): 5083. http://dx.doi.org/10.1158/1538-7445.am2022-5083.
Testo completo